타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Dupixent (dupilumab) |
Overview Company | Sanofi / Regeneron |
Overview Modality | ANTIBODY |
Overview Target | IL-4Rα |
Overview Indication | Atopic dermatitis, asthma, CRSwNP, EoE, prurigo nodularis |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Novel targets under investigation include MRGPRs, PARs, KIT receptors, OX-40, and sodium channels |
Positioning Known limitation | Non-Type 2 inflammation and inadequate trough levels. |
MoA Mechanism | Dupilumab binds IL-4Rα subunit shared by IL-4 type I and IL-13 type II receptors, inhibiting IL-4 and IL-13 signaling, reducing Type 2 inflammation (IgE, eosinophils, Th2 cytokines). |
MoA Biomarker | biomarkers and clinical characteristics and highlight the need for standardized, methodologically rigorous fu |
Toxicology Species | Mouse |
Toxicology Major finding | Conjunctivitis, injection-site reactions, eosinophilia; herpes zoster caution. |
Toxicology CRS | N/A |
Clinical Safety signal | Conjunctivitis, injection-site reactions, eosinophilia; herpes zoster caution. |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Dupixent (dupilumab) |
Overview Company | Sanofi / Regeneron |
Overview Modality | ANTIBODY |
Overview Target | IL-4Rα |
Overview Indication | Atopic dermatitis, asthma, CRSwNP, EoE, prurigo nodularis |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Novel targets under investigation include MRGPRs, PARs, KIT receptors, OX-40, and sodium channels |
Positioning Known limitation | Non-Type 2 inflammation and inadequate trough levels. |
MoA Mechanism | Dupilumab binds IL-4Rα subunit shared by IL-4 type I and IL-13 type II receptors, inhibiting IL-4 and IL-13 signaling, reducing Type 2 inflammation (IgE, eosinophils, Th2 cytokines). |
MoA Biomarker | biomarkers and clinical characteristics and highlight the need for standardized, methodologically rigorous fu |
Toxicology Species | Mouse |
Toxicology Major finding | Conjunctivitis, injection-site reactions, eosinophilia; herpes zoster caution. |
Toxicology CRS | N/A |
Clinical Safety signal | Conjunctivitis, injection-site reactions, eosinophilia; herpes zoster caution. |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
추천 비교
추천 비교